[Expert Consensus on the Diagnosis and Treatment of Respiratory Diseases Exacerbated by Nonsteroidal Anti-inflammatory Drugs （2024, Chengdu）]

Overview

Journal Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi

Specialty Otorhinolaryngology

Date 2024 Jun 10

PMID 38858107

Authors

Juan Meng

Jing Ye

Lijiang Zhang

Yuanteng Xu

Wenlong Liu

Yucheng Yang

Xiangdong Wang

Yan Jiang

Qianhui Qiu

Jian Li

Shaoqing Yu

Feng Liu

HongFei Lou

Hongtian Wang

Guodong Yu

Rui Xu

Cuida Meng

Na Sun

Jianjun Chen

Ming Zeng

Zhihai Xie

YueJi Sun

Juan Tang

Keqing Zhao

Weitian Zhang

Zhaohui Shi

Chengli Xu

Yanli Yang

Meiping Lu

Huiping Ye

Xin Wei

Bin Sun

Yunfang An

Yanan Sun

Yurong Gu

TianHong Zhang

Luo Ba

Qintai Yang

Yu Xu

Gui Yang

Haiyu Hong

KeJun Zuo

Huabin Li

Affiliations

Soon will be listed here.

Abstract

Non-steroidal anti-inflammatory drugs-exacerbated respiratory disease （N-ERD） is a chronic respiratory disease characterized by eosinophilic inflammation, featuring chronic rhinosinusitis （CRS）, asthma, and intolerance to cyclooxygenase 1 （COX-1） inhibitors. The use of these medications can lead to an acute worsening of rhinitis and asthma symptoms. This condition has not yet received sufficient attention in China, with a high rate of misdiagnosis and a lack of related research. The Chinese Rhinology Research Group convened a group of leading young experts in otolaryngology from across the country, based on the latest domestic and international evidence-based medical practices to formulate this consensus.The consensus covers the epidemiology, pathogenesis, clinical manifestations, diagnostic methods, and treatment strategies for N-ERD, including pharmacotherapy, surgery, biologic treatments, and desensitization therapy. The goal is to improve recognition of N-ERD, reduce misdiagnosis, and enhance treatment outcomes.

References

Patriarca G, Bellioni P, Nucera E, Schiavino D, Papa G, Schinco G . Intranasal treatment with lysine acetylsalicylate in patients with nasal polyposis. Ann Allergy. 1991; 67(6):588-92. View

Nizankowska E, Bestynska-Krypel A, Cmiel A, Szczeklik A . Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma. Eur Respir J. 2000; 15(5):863-9. DOI: 10.1034/j.1399-3003.2000.15e09.x. View

Wangberg H, Spierling Bagsic S, Osuna L, White A . Appraisal of the Real-World Effectiveness of Biologic Therapies in Aspirin-Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract. 2021; 10(2):478-484.e3. PMC: 8837666. DOI: 10.1016/j.jaip.2021.09.030. View

Lin K, Hernandez-Diaz S, Garcia Rodriguez L . Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy. Gastroenterology. 2011; 141(1):71-9. DOI: 10.1053/j.gastro.2011.03.049. View

Meng Y, Lou H, Wang C, Zhang L . Predictive significance of computed tomography in eosinophilic chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2016; 6(8):812-9. DOI: 10.1002/alr.21749. View

Levy J, Rudmik L, Peters A, Wise S, Rotenberg B, Smith T . Contemporary management of chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease: an evidence-based review with recommendations. Int Forum Allergy Rhinol. 2016; 6(12):1273-1283. PMC: 5140738. DOI: 10.1002/alr.21826. View

Morales D, Guthrie B, Lipworth B, Jackson C, Donnan P, Santiago V . NSAID-exacerbated respiratory disease: a meta-analysis evaluating prevalence, mean provocative dose of aspirin and increased asthma morbidity. Allergy. 2015; 70(7):828-35. DOI: 10.1111/all.12629. View

Stevenson D . Diagnosis, prevention, and treatment of adverse reactions to aspirin and nonsteroidal anti-inflammatory drugs. J Allergy Clin Immunol. 1984; 74(4 Pt 2):617-22. DOI: 10.1016/0091-6749(84)90115-5. View

Bergmark R, Palumbo M, Rahman S, Maurer R, Dominas C, Roditi R . Aspirin-Exacerbated Respiratory Disease: Association Between Patient-Reported Sinus and Asthma Morbidity. J Allergy Clin Immunol Pract. 2020; 9(4):1604-1611. DOI: 10.1016/j.jaip.2020.11.051. View

10.

Jenkins C, Costello J, Hodge L . Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ. 2004; 328(7437):434. PMC: 344260. DOI: 10.1136/bmj.328.7437.434. View

11.

Ramirez-Jimenez F, Vazquez-Corona A, Sanchez-de la Vega Reynoso P, Pavon-Romero G, Jimenez-Chobillon M, Castorena-Maldonado A . Effect of LTRA in L-ASA Challenge for Aspirin-Exacerbated Respiratory Disease Diagnosis. J Allergy Clin Immunol Pract. 2020; 9(4):1554-1561. DOI: 10.1016/j.jaip.2020.10.041. View

12.

Gevaert P, Omachi T, Corren J, Mullol J, Han J, Lee S . Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020; 146(3):595-605. DOI: 10.1016/j.jaci.2020.05.032. View

13.

White A, Stevenson D, Simon R . The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2005; 95(4):330-5. DOI: 10.1016/S1081-1206(10)61150-7. View

14.

Weber R, Hoffman M, Raine Jr D, Nelson H . Incidence of bronchoconstriction due to aspirin, azo dyes, non-azo dyes, and preservatives in a population of perennial asthmatics. J Allergy Clin Immunol. 1979; 64(1):32-7. DOI: 10.1016/0091-6749(79)90080-0. View

15.

Fokkens W, Lund V, Hopkins C, Hellings P, Kern R, Reitsma S . European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020; 58(Suppl S29):1-464. DOI: 10.4193/Rhin20.600. View

16.

Ledford D, Lockey R . Aspirin or Nonsteroidal Anti-inflammatory Drug-Exacerbated Chronic Rhinosinusitis. J Allergy Clin Immunol Pract. 2016; 4(4):590-8. DOI: 10.1016/j.jaip.2016.04.011. View

17.

Stevenson D, Simon R . Selection of patients for aspirin desensitization treatment. J Allergy Clin Immunol. 2006; 118(4):801-4. DOI: 10.1016/j.jaci.2006.06.019. View

18.

Mastalerz L, Nizankowska E, Sanak M, Mejza F, Pierzchalska M, Bazan-Socha S . Clinical and genetic features underlying the response of patients with bronchial asthma to treatment with a leukotriene receptor antagonist. Eur J Clin Invest. 2003; 32(12):949-55. DOI: 10.1046/j.1365-2362.2002.01088.x. View

19.

Rodriguez-Jimenez J, Moreno-Paz F, Teran L, Guani-Guerra E . Aspirin exacerbated respiratory disease: Current topics and trends. Respir Med. 2018; 135:62-75. DOI: 10.1016/j.rmed.2018.01.002. View

20.

Roca-Ferrer J, Garcia-Garcia F, Pereda J, Perez-Gonzalez M, Pujols L, Alobid I . Reduced expression of COXs and production of prostaglandin E(2) in patients with nasal polyps with or without aspirin-intolerant asthma. J Allergy Clin Immunol. 2011; 128(1):66-72.e1. DOI: 10.1016/j.jaci.2011.01.065. View